Amgen operates a high-quality franchise with 21% operating margins and four consecutive earnings beats averaging over 11% above estimates, but 77% of revenue flows through three distributors, the dividend yield may be unsustainable, and the stock sits within 0.2% of its near-term resistance target with a negative risk/reward — the setup favors holding an existing position rather than adding.
Thesis pillars
- High Quality Franchise Margins→Stable
- Consistent Earnings Beat Streak→Stable
- Distributor Concentration Vulnerability↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 13, 2026
Amgen Inc. (AMGN) Stock Analysis
Healthcare · Drug Manufacturers - General
Sell if holding. At $451.83, A.R:R is negative (-1.7) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Customer: McKesson, Cencora, and Cardinal Health (77.0%); Concentration risk — Geographic: United States (73.0%).
Amgen discovers, develops, manufactures, and delivers biotechnology medicines across approximately 100 countries in one segment—human therapeutics—generating $35,148 million in product sales in 2025 (73% U.S., 27% rest of world). Three wholesale distributors (McKesson, Cencora,... Read more
Sell if holding. At $451.83, A.R:R is negative (-1.7) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Customer: McKesson, Cencora, and Cardinal Health (77.0%); Concentration risk — Geographic: United States (73.0%). Chart setup: No clear chart pattern; technical signals are mixed. Score 6.0/10, moderate confidence.
Passes 4/7 gates (positive momentum, clean insider activity, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and earnings proximity 5d<=7d. Suitability: conservative.
About Amgen Inc.
About Amgen Inc.
Amgen posted $35,148 million in product sales in 2025, with the United States representing 73% ($25,656 million) and rest-of-world 27% ($9,492 million). Products with significant 2025 milestones include UPLIZNA (two new FDA approvals—IgG4-RD in April and generalized myasthenia gravis in December), IMDELLTRA/IMDYLLTRA (Phase 3 showed 40% reduction in death risk versus chemotherapy; full FDA approval November 2025), and TEPEZZA (European Commission approval June 2025). MariTide has six global Phase 3 studies underway as of late 2025.
Amgen distributes products in the United States primarily through three large wholesale distributors—McKesson Corporation, Cencora, Inc., and Cardinal Health, Inc.—which collectively accounted for 77% of worldwide gross revenues in 2025, with each individually exceeding 10% of total revenues. Internationally, the company sells through its own affiliates, third-party distributors, and partnerships in Asia Pacific with Astellas Pharma, BeOne, Mitsubishi Tanabe Pharma, Takeda Pharmaceutical, and Kyowa Kirin. Commercial manufacturing is concentrated at the company's facility in the U.S. territory of Puerto Rico, with clinical manufacturing centered in Thousand Oaks, California. Key patent events include the expiration of RANKL antibody patents for Prolia and XGEVA in February 2025 (U.S.) and November 2025 (Europe), with multiple biosimilars already launched, accelerating sales erosion. CMS set a Medicare Part D price for ENBREL effective January 1, 2026, and for Otezla effective January 2027, at significantly lower prices expected to reduce profitability in Medicare.
Show full overview
ENBREL faces compounding pricing pressure: CMS set a Medicare Part D price effective January 1, 2026 at significantly lower levels expected to reduce profitability in Medicare, and Colorado's PDAB established an Upper Payment Limit for ENBREL effective no earlier than January 1, 2027, with Washington state initiating a parallel affordability review in July 2025. RANKL antibody patents for Prolia and XGEVA already expired in early 2025, with multiple biosimilars launched and accelerated erosion underway—demonstrating the trajectory that may follow if U.S.-approved ENBREL biosimilars launch. Otezla faces IRA-mandated Medicare price-setting effective January 2027.
See also: Healthcare · Drug Manufacturers - General
From Amgen Inc.'s most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated 2026-10-29Recent Developments — Amgen Inc.
Latest news
- NEWS Amgen (AMGN) Stock Moves -1.44%: What You Should Know - Yahoo Finance — Yahoo Finance neutral
- NEWS Amgen (AMGN) Stock Moves -1.44%: What You Should Know - finance.yahoo.com — finance.yahoo.com neutral
- NEWS Amgen (NASDAQ:AMGN) Stock Price Expected to Rise, Barclays Analyst Says - MarketBeat — MarketBeat positive
- NEWS California State Teachers Retirement System Sells 19,940 Shares of Amgen Inc. $AMGN - MarketBeat — MarketBeat neutral
- NEWS Amgen Inc. $AMGN Stock Position Reduced by Amundi - MarketBeat — MarketBeat negative
Generated 2026-10-29T10:28:31Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHCustomerMcKesson, Cencora, and Cardinal Health77%10-K Item 1: 'product sales to three large wholesalers, McKesson Corporation, Cencora, Inc. and Cardinal Health, Inc. ... accounted for 77%, 77% and 79% of worldwide gross revenues for 2025'
- HIGHGeographicUnited States73%10-K Item 1: 'United States as our largest market ... U.S.| $| 25,656 | | 73 | %'
Material Events(8-K, last 90d)
- 2026-05-19Item 5.02MEDIUMCFO Peter H. Griffith announced retirement effective Aug 31, 2026. Successor Thomas Dittrich named as EVP and CFO effective Sept 1, 2026; Dittrich will initially be based in Rotkreuz, Switzerland before relocating to Thousand Oaks, CA.SEC filing →
- 2026-04-22Item 5.02MEDIUMEVP and CTO David M. Reese retiring June 30, 2026. Role eliminated; responsibilities redistributed to J. Bradner (R&D/AI), M. Gordon (Global Markets), and P. Griffith (CFO) effective June 1, 2026. Reese retirement-eligible; receives standard retirement benefits.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
10 dimensions · all in-band
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $451.83, A.R:R is negative (-1.7) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Customer: McKesson, Cencora, and Cardinal Health (77.0%); Concentration risk — Geographic: United States (73.0%). Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $429.99. Score 6.0/10, moderate confidence.
Analyst target $357.59 reached (−20.9% from $451.83); no take-profit level is published. Prior stop was $429.99. Stop-loss: $429.99.
Concentration risk — Customer: McKesson, Cencora, and Cardinal Health (77.0%); Concentration risk — Geographic: United States (73.0%); Analyst target reached - limited upside remaining.
Amgen Inc. trades at a P/E of 28.1 (forward 18.4). TrendMatrix value score: 4.4/10. Verdict: Sell.
42 analysts cover AMGN with a consensus score of 3.5/5. Average price target: $397.
What does Amgen Inc. do?Amgen discovers, develops, manufactures, and delivers biotechnology medicines across approximately 100 countries in one...
Amgen discovers, develops, manufactures, and delivers biotechnology medicines across approximately 100 countries in one segment—human therapeutics—generating $35,148 million in product sales in 2025 (73% U.S., 27% rest of world). Three wholesale distributors (McKesson, Cencora, Cardinal Health) collectively account for 77% of worldwide gross revenues.